173 related articles for article (PubMed ID: 12736120)
1. NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Woon ST; Zwain S; Schooltink MA; Newth AL; Baguley BC; Ching LM
Eur J Cancer; 2003 May; 39(8):1176-83. PubMed ID: 12736120
[TBL] [Abstract][Full Text] [Related]
2. The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor.
Philpott M; Ching LM; Baguley BC
Eur J Cancer; 2001 Oct; 37(15):1930-7. PubMed ID: 11576850
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the ability of DMXAA and xanthenone analogues to activate NF-kappaB in murine and human cell lines.
Woon ST; Reddy CB; Drummond CJ; Schooltink MA; Baguley BC; Kieda C; Ching LM
Oncol Res; 2005; 15(7-8):351-64. PubMed ID: 16491953
[TBL] [Abstract][Full Text] [Related]
4. Uptake of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and activation of NF-kappaB in human tumor cell lines.
Woon ST; Baguley BC; Palmer BD; Fraser JD; Ching LM
Oncol Res; 2002; 13(2):95-101. PubMed ID: 12392157
[TBL] [Abstract][Full Text] [Related]
5. Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice.
Zhao L; Kestell P; Ching LM; Baguley BC
Cancer Chemother Pharmacol; 2002 Jan; 49(1):20-6. PubMed ID: 11855749
[TBL] [Abstract][Full Text] [Related]
6. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice.
Ching LM; Goldsmith D; Joseph WR; Körner H; Sedgwick JD; Baguley BC
Cancer Res; 1999 Jul; 59(14):3304-7. PubMed ID: 10416582
[TBL] [Abstract][Full Text] [Related]
7. DMXAA: an antivascular agent with multiple host responses.
Baguley BC; Ching LM
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1503-11. PubMed ID: 12459378
[TBL] [Abstract][Full Text] [Related]
8. Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Zhao L; Kestell P; Philpott M; Ching LM; Zhuang L; Baguley BC
Cancer Chemother Pharmacol; 2001 Jun; 47(6):491-7. PubMed ID: 11459201
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM
Br J Cancer; 1999 May; 80(5-6):716-23. PubMed ID: 10360649
[TBL] [Abstract][Full Text] [Related]
10. The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice.
Zhao L; Ching LM; Kestell P; Baguley BC
Br J Cancer; 2002 Aug; 87(4):465-70. PubMed ID: 12177785
[TBL] [Abstract][Full Text] [Related]
11. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity.
Ching LM; Browne WL; Tchernegovski R; Gregory T; Baguley BC; Palmer BD
Br J Cancer; 1998 Aug; 78(3):336-43. PubMed ID: 9703279
[TBL] [Abstract][Full Text] [Related]
12. Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid.
Browne WL; Wilson WR; Baguley BC; Ching LM
Anticancer Res; 1998; 18(6A):4409-13. PubMed ID: 9891501
[TBL] [Abstract][Full Text] [Related]
13. Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid.
Philpott M; Baguley BC; Ching LM
Cancer Chemother Pharmacol; 1995; 36(2):143-8. PubMed ID: 7767951
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy.
Joseph WR; Cao Z; Mountjoy KG; Marshall ES; Baguley BC; Ching LM
Cancer Res; 1999 Feb; 59(3):633-8. PubMed ID: 9973211
[TBL] [Abstract][Full Text] [Related]
15. Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Cao Z; Baguley BC; Ching LM
Cancer Res; 2001 Feb; 61(4):1517-21. PubMed ID: 11245459
[TBL] [Abstract][Full Text] [Related]
16. Antitumour activity of the novel immune modulator 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice lacking the interferon-gamma receptor.
Pang JH; Cao Z; Joseph WR; Baguley BC; Ching LM
Eur J Cancer; 1998 Jul; 34(8):1282-9. PubMed ID: 9849492
[TBL] [Abstract][Full Text] [Related]
17. NF-kappaB-independent induction of endothelial cell apoptosis by the vascular disrupting agent DMXAA.
Woon ST; Hung SS; Wu DC; Schooltink MA; Sutherland R; Baguley BC; Chen Q; Chamley LW; Ching LM
Anticancer Res; 2007; 27(1A):327-34. PubMed ID: 17352250
[TBL] [Abstract][Full Text] [Related]
18. Antivascular therapy of cancer: DMXAA.
Baguley BC
Lancet Oncol; 2003 Mar; 4(3):141-8. PubMed ID: 12623359
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of DMXAA-induced tumor necrosis factor production in murine splenocyte cultures by NF-kappaB inhibitors.
Wang LC; Woon ST; Baguley BC; Ching LM
Oncol Res; 2006; 16(1):1-14. PubMed ID: 16783963
[TBL] [Abstract][Full Text] [Related]
20. Induction of STAT and NFkappaB activation by the antitumor agents 5,6-dimethylxanthenone-4-acetic acid and flavone acetic acid in a murine macrophage cell line.
Ching LM; Young HA; Eberly K; Yu CR
Biochem Pharmacol; 1999 Oct; 58(7):1173-81. PubMed ID: 10484075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
